Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).

Monroe SE, Blumenfeld Z, Andreyko JL, Schriock E, Henzl MR, Jaffe RB

The Journal of clinical endocrinology and metabolism1 Dec 1986Cited by 31 (Europe PMC)

PMID2946710DOI10.1210/jcem-63-6-1334PepBankPUB-02946710

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, basal FSH decreased in all nafarelin dose groups, with P less than 0.01.
In plain wordsIn women with ovulatory cycles, basal FSH decreased in all nafarelin dose groups.
Peptide
Nafarelin
Outcome
DecreaseBasal FSH
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125, 250 or 1000 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Basal serum FSH concentrations decreased (P less than 0.01) in all groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671001
02HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, serum LH suppression with nafarelin 125 micrograms daily was not significant; it was significant (P less than 0.01) only at 250 and 1000 micrograms.
In plain wordsIn women with ovulatory cycles, the LH drop with 125 micrograms of nafarelin was not statistically significant.
Peptide
Nafarelin
Outcome
No significant changeSerum LH at lower dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Suppression of serum LH was dose dependent and significant (P less than 0.01) only in Gps II and III.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671002
03HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, nafarelin 250 micrograms significantly suppressed LH, with P less than 0.01.
In plain wordsIn women with ovulatory cycles, nafarelin 250 micrograms significantly suppressed LH.
Peptide
Nafarelin
Outcome
DecreaseSerum LH at middle dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
250 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Suppression of serum LH was dose dependent and significant (P less than 0.01) only in Gps II and III.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671003
04HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, nafarelin 1000 micrograms significantly suppressed LH, with P less than 0.01.
In plain wordsIn women with ovulatory cycles, nafarelin 1000 micrograms significantly suppressed LH.
Peptide
Nafarelin
Outcome
DecreaseSerum LH at higher dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1000 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Suppression of serum LH was dose dependent and significant (P less than 0.01) only in Gps II and III.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671004
05HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, pituitary desensitization to nafarelin developed in all dose groups.
In plain wordsIn women with ovulatory cycles, the pituitary became less responsive to nafarelin in all dose groups.
Peptide
Nafarelin
Outcome
DecreasePituitary desensitization
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125, 250 or 1000 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Pituitary desensitization to nafarelin developed in all groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671005
06HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, peak LH responses to nafarelin decreased about 70% in the lower dose groups.
In plain wordsIn women with ovulatory cycles, peak LH responses to nafarelin decreased about 70% in the lower dose groups.
Peptide
Nafarelin
Outcome
DecreasePeak LH response at lower doses
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125 or 250 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Decrease in peak LH response to nafarelin
≈ 70%
Gps I and II (125 and 250 micrograms daily)
Source sentences
Summary
Peak LH responses to nafarelin decreased by about 70% (Gps I and II) and 95% (Gp III).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671006
07HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, peak LH responses to nafarelin decreased about 95% in the highest dose group.
In plain wordsIn women with ovulatory cycles, peak LH responses to nafarelin decreased about 95% in the highest dose group.
Peptide
Nafarelin
Outcome
DecreasePeak LH response at higher dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1000 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Decrease in peak LH response to nafarelin
≈ 95%
Gp III (1000 micrograms daily)
Source sentences
Summary
Peak LH responses to nafarelin decreased by about 70% (Gps I and II) and 95% (Gp III).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671007
08HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, basal estradiol was approximately 70 pg/ml after 1 month of lower-dose nafarelin.
In plain wordsIn women with ovulatory cycles, basal estradiol was about 70 pg/ml after 1 month of lower-dose nafarelin.
Peptide
Nafarelin
Outcome
Not applicableEstradiol at one month, lower dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125 micrograms daily · intranasal spray · 1 monthAs given in this study (human).
Measurements
Basal serum estradiol
≈ 70 pg/ml
after 1 month, Gp I (125 micrograms daily)
Source sentences
Summary
Basal serum estradiol levels after 1 month of treatment were approximately 70 pg/ml (Gp I) and 25 pg/ml (Gps II and III).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671008
09HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, basal estradiol was approximately 25 pg/ml after 1 month in the higher nafarelin dose groups.
In plain wordsIn women with ovulatory cycles, basal estradiol was about 25 pg/ml after 1 month in the higher nafarelin dose groups.
Peptide
Nafarelin
Outcome
Not applicableEstradiol at one month, higher doses
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
250 or 1000 micrograms daily · intranasal spray · 1 monthAs given in this study (human).
Measurements
Basal serum estradiol
≈ 25 pg/ml
after 1 month, Gps II and III (250 and 1000 micrograms daily)
Source sentences
Summary
Basal serum estradiol levels after 1 month of treatment were approximately 70 pg/ml (Gp I) and 25 pg/ml (Gps II and III).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671009
10HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, estradiol increased acutely after each nafarelin dose in the lower dose groups.
In plain wordsIn women with ovulatory cycles, estradiol rose after each nafarelin dose in the lower dose groups.
Peptide
Nafarelin
Outcome
IncreaseAcute estradiol response at lower doses
Study
n: not reported in source
Comparator
Before each dose
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125 or 250 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Serum estradiol levels increased acutely in Gps I and II, but not in Gp III, in response to each dose of nafarelin.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671010
11HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, estradiol did not increase acutely after each nafarelin dose in the highest dose group.
In plain wordsIn women with ovulatory cycles, estradiol did not rise after each nafarelin dose in the highest dose group.
Peptide
Nafarelin
Outcome
No significant changeAcute estradiol response at higher dose
Study
n: not reported in source
Comparator
Before each dose
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1000 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Serum estradiol levels increased acutely in Gps I and II, but not in Gp III, in response to each dose of nafarelin.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671011
12HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, average daily estradiol was higher with nafarelin 250 micrograms than with 1000 micrograms.
In plain wordsIn women with ovulatory cycles, average estradiol was higher with nafarelin 250 micrograms than with 1000 micrograms.
Peptide
Nafarelin
Outcome
IncreaseAverage daily estradiol between doses
Study
n: not reported in source
Comparator
Nafarelin 1000 micrograms daily
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
250 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Thus, average daily estradiol levels in Gp II were higher than those in Gp III.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671012
13HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, testosterone decreased slightly during nafarelin treatment in the middle dose group, with P less than 0.05.
In plain wordsIn women with ovulatory cycles, testosterone decreased slightly during nafarelin treatment in the middle dose group.
Peptide
Nafarelin
Outcome
DecreaseTestosterone at middle dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
250 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Serum testosterone and androstenedione levels decreased slightly (P less than 0.05; Gp II) or by 50% (P less than 0.01; Gp III) during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671013
14HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, androstenedione decreased slightly during nafarelin treatment in the middle dose group, with P less than 0.05.
In plain wordsIn women with ovulatory cycles, androstenedione decreased slightly during nafarelin treatment in the middle dose group.
Peptide
Nafarelin
Outcome
DecreaseAndrostenedione at middle dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
250 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
Serum testosterone and androstenedione levels decreased slightly (P less than 0.05; Gp II) or by 50% (P less than 0.01; Gp III) during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671014
15HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, testosterone decreased by 50% in the highest nafarelin dose group, with P less than 0.01.
In plain wordsIn women with ovulatory cycles, testosterone decreased by 50% in the highest nafarelin dose group.
Peptide
Nafarelin
Outcome
DecreaseTestosterone at higher dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1000 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Testosterone decrease
50%
Gp III, 1000 micrograms daily
Source sentences
Summary
Serum testosterone and androstenedione levels decreased slightly (P less than 0.05; Gp II) or by 50% (P less than 0.01; Gp III) during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671015
16HumanNon-randomized trialEfficacy outcome
In women with ovulatory cycles, androstenedione decreased by 50% in the highest nafarelin dose group, with P less than 0.01.
In plain wordsIn women with ovulatory cycles, androstenedione decreased by 50% in the highest nafarelin dose group.
Peptide
Nafarelin
Outcome
DecreaseAndrostenedione at higher dose
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1000 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Androstenedione decrease
50%
Gp III, 1000 micrograms daily
Source sentences
Summary
Serum testosterone and androstenedione levels decreased slightly (P less than 0.05; Gp II) or by 50% (P less than 0.01; Gp III) during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671016
17HumanNon-randomized trialEfficacy outcome
In women receiving lower-dose nafarelin, four ovulations with progesterone greater than 4 ng/ml occurred during 73 treatment months.
In plain wordsIn women receiving lower-dose nafarelin, four ovulations occurred during 73 treatment months.
Peptide
Nafarelin
Outcome
Not applicableOvulations at lower dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Ovulations
4 ovulations
Gp I, 125 micrograms daily
Observation period
73 months
Gp I, nafarelin administration
Source sentences
Summary
In Gp I there were four ovulations (progesterone, greater than 4 ng/ml) and seven instances of luteinization (progesterone, 2-4 ng/ml) during 73 months of nafarelin administration.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671017
18HumanNon-randomized trialEfficacy outcome
In women receiving lower-dose nafarelin, seven luteinization episodes with progesterone 2-4 ng/ml occurred during 73 treatment months.
In plain wordsIn women receiving lower-dose nafarelin, seven luteinization episodes occurred during 73 treatment months.
Peptide
Nafarelin
Outcome
Not applicableLuteinization at lower dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Instances of luteinization
7 instances
Gp I, 125 micrograms daily
Observation period
73 months
Gp I, nafarelin administration
Source sentences
Summary
In Gp I there were four ovulations (progesterone, greater than 4 ng/ml) and seven instances of luteinization (progesterone, 2-4 ng/ml) during 73 months of nafarelin administration.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671018
19HumanNon-randomized trialEfficacy outcome
In women receiving middle-dose nafarelin, no ovulations occurred during 58 treatment months.
In plain wordsIn women receiving middle-dose nafarelin, no ovulations occurred during 58 treatment months.
Peptide
Nafarelin
Outcome
Not applicableOvulation at middle dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
250 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Observation period
58 months
Gp II, nafarelin administration
Source sentences
Summary
In contrast, there were no ovulations during 58 and 44 months in Gps II and III, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671019
20HumanNon-randomized trialEfficacy outcome
In women receiving highest-dose nafarelin, no ovulations occurred during 44 treatment months.
In plain wordsIn women receiving highest-dose nafarelin, no ovulations occurred during 44 treatment months.
Peptide
Nafarelin
Outcome
Not applicableOvulation at higher dose
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1000 micrograms daily · intranasal sprayAs given in this study (human).
Measurements
Observation period
44 months
Gp III, nafarelin administration
Source sentences
Summary
In contrast, there were no ovulations during 58 and 44 months in Gps II and III, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671020
21HumanNon-randomized trialEfficacy outcome
In women after nafarelin discontinuation, ovulatory menstrual function returned rapidly in all participants.
In plain wordsIn women, ovulatory menstrual function returned rapidly after nafarelin ended.
Peptide
Nafarelin
Outcome
Not applicableOvulatory menstrual recovery
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
125, 250 or 1000 micrograms daily · intranasal sprayAs given in this study (human).
Source sentences
Summary
After discontinuance of nafarelin, ovulatory menstrual function returned rapidly in all women.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two women with ovulatory menstrual cycles were given 125 micrograms (group (Gp) I), 250 micrograms (Gp II), or 1000 micrograms (Gp III) nafarelin daily by intranasal spray.
Summary · context
Twenty-seven women completed 6 months of treatment.
Report a problemFND-0294671021

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.